References
- Chou WC, Hung YS, Hsu JT, et al (2012). Chromogranin a is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology, 95, 344-50. https://doi.org/10.1159/000333853
- Chua W, Charles K, Baracos V, Clarke S (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Bri J Cancer, 104, 1288-95. https://doi.org/10.1038/bjc.2011.100
- Dogan M, Yalcin B, Ozdemir NY, et al (2012). Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature. Med Oncol, 29, 2021-6. https://doi.org/10.1007/s12032-011-9986-9
- Hauso O, Gustafsson BI, Kidd M, et al (2008). Neuroendocrine tumor epidemiology. Cancer, 113, 2655-64. https://doi.org/10.1002/cncr.23883
- Jensen KH, Hilsted L, Jensen C, et al (2013). Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scandinavian J Gastroenterol, 48, 70-7. https://doi.org/10.3109/00365521.2012.733953
- Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010). The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas, 39, 707-12. https://doi.org/10.1097/MPA.0b013e3181ec124e
- Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P (2007). Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Archiv, 451, 9-27. https://doi.org/10.1007/s00428-007-0461-0
- Korse CM, Taal BG, Vincent A, et al (2012). Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer, 48, 662-71. https://doi.org/10.1016/j.ejca.2011.08.012
- Kulke MH, Siu LL, Tepper JE, et al (2011). Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol, 29, 934-43. https://doi.org/10.1200/JCO.2010.33.2056
- Lepage C, Rachet B, Coleman MP (2007). Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterol, 132, 899-904. https://doi.org/10.1053/j.gastro.2007.01.006
- Lepage C, Ciccolallo L, De Angelis R, et al (2010). European disparities in malignant digestive endocrine tumours survival. Int J Cancer, 126, 2928-34.
- Lloyd RV (2003). Practical markers used in the diagnosis of neuroendocrine tumors. Endocrine Pathol, 14, 293-301. https://doi.org/10.1385/EP:14:4:293
- Maggard MA, O’Connell JB, Ko CY (2004). Updated population-based review of carcinoid tumors. Ann Surg, 240, 117. https://doi.org/10.1097/01.sla.0000129342.67174.67
- Massironi S, Spampatti MP, Rossi RE, et al (2012). Circulating Markers in Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs). In: A. Lowell (ed.), NEUROENDOCRINE TUMOR. In Tech, Croatia.
- Metz DC, Jensen RT (2008). Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology, 135, 1469-92. https://doi.org/10.1053/j.gastro.2008.05.047
- Mougey AM, Adler DG (2007). Neuroendocrine tumors: review and clinical update. Hospital Physician, 43, 12.
- Ozyalvacli G, Pasaoglu E, Bozkurt ER (2012). Gastrointestinal and Pancreatic Neuroendocrine Tumors Prognostic Parameters. Abant Med J, 1, 69-72. https://doi.org/10.5505/abantmedj.2012.02411
- Rindi G, Arnold R, Bosman F, et al (2010). Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO Classification of Tumours of the Digestive System, 13-4.
- Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997). Prognostic value of tumour infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol, 182, 318-24. https://doi.org/10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6
- Sarraf KM, Belcher E, Raevsky E, et al (2009): Neutrophil/lymphocyte ratio and its association with survival after complete resection in non.small cell lung cancer. J Thoracic and Cardiovascular Surg, 137, 425-8. https://doi.org/10.1016/j.jtcvs.2008.05.046
- Shayanfar N, Shahzadi SZ (2009). Immunohistochemical assessment of neuroendocrine differentiation in colorectal carcinomas and Its relation with age, sex and grade plus stage. Iranian J Pathol, 4, 167-71.
- Shimada H, Takiguchi N, Kainuma O, et al (2010). High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer, 13, 170-6. https://doi.org/10.1007/s10120-010-0554-3
- Stojsic J, Stevic R, Kontic M, et al (2011). Large cell lung carcinoma with unusual imaging feature, immunophenotype and genetic finding. Pathol and Oncol Res, 17, 175-9. https://doi.org/10.1007/s12253-010-9272-8
- Stoyianni A, Pentheroudakis G, Pavlidis N (2011). Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treatment Rev, 37, 358-65. https://doi.org/10.1016/j.ctrv.2011.03.002
- Tavassoli FA, Devilee P (2003). Pathology and genetics: tumours of the breast and female genital organs. International Agency for Research on Cancer, Lyon.
- Travis WD, Rush W, Flieder DB, et al (1998). Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol, 22, 934-44. https://doi.org/10.1097/00000478-199808000-00003
- Walsh S, Cook E, Goulder F, Justin T, Keeling N (2005). Neutrophil lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. https://doi.org/10.1002/jso.20329
- Yao JC, Hassan M, Phan A, et al (2008). One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. J Clin Oncol, 26, 3063-72. https://doi.org/10.1200/JCO.2007.15.4377
- Yao JC, Shah MH, Ito T, et al (2011). Everolimus for advanced pancreatic neuroendocrine tumors. New England J Med, 364, 514-23. https://doi.org/10.1056/NEJMoa1009290
- Yao JC, Lagunes DR, Kulke MH (2013). Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned. The Oncologist, 18, 525-32. https://doi.org/10.1634/theoncologist.2012-0434
- Yildiz O, Ozguro.lu M, Yanmaz T, et al (2010). Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center. Med Oncol, 27, 1050-6. https://doi.org/10.1007/s12032-009-9332-7
- Yildiz O, Serdengecti S (2012). Gastrointestinal Neuroendocrine Tumors. In: A. Lowell (ed.), Neuroendocrine Tumor. In Tech, Croatia.
- Zjacic-Rotkvic V, Berkovic M (2010). Neuroendocrine tumors (NET) of the gastrointestinal system: diagnosis and therapy. Acta Clin Croatica, 49, 224-5.
Cited by
- Predictive Role of the Neutrophil Lymphocyte Ratio for Invasion with Gestational Trophoblastic Disease vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4203
- Somatostatin Analogues Do Not Prevent Carcinoid Crisis vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6679
- Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7835
- Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2089
- Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2205